Northern Trust’s Organogenesis Holdings ORGO Stock Holding History

Northern Trust’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Buy	584,577 +30,149	+5%	+$73.7K	﹤0.01%	3329
2026 Q1	$1.31M	Buy	554,428 +20,126	+4%	+$69.7K	﹤0.01%	3200
2025 Q4	$2.77M	Sell	534,302 -59,805	-10%	-$290K	﹤0.01%	2802
2025 Q3	$2.51M	Sell	594,107 -194,066	-25%	-$902K	﹤0.01%	2910
2025 Q2	$2.88M	Buy	788,173 +194,780	+33%	+$726K	﹤0.01%	2790
2025 Q1	$2.56M	Sell	593,393 -22,696	-4%	-$91.6K	﹤0.01%	2790
2024 Q4	$1.97M	Buy	616,089 +17,196	+3%	+$57.7K	﹤0.01%	3035
2024 Q3	$1.71M	Buy	598,893 +9,898	+2%	+$27.8K	﹤0.01%	3094
2024 Q2	$1.65M	Sell	588,995 -27,594	-4%	-$74.1K	﹤0.01%	3008
2024 Q1	$1.75M	Sell	616,589 -9,318	-1%	-$31.7K	﹤0.01%	3037
2023 Q4	$2.56M	Buy	625,907 +3,271	+0.5%	+$9.16K	﹤0.01%	2863
2023 Q3	$1.98M	Buy	622,636 +21,526	+4%	+$68.4K	﹤0.01%	2945
2023 Q2	$2M	Sell	601,110 -96,192	-14%	-$284K	﹤0.01%	3005
2023 Q1	$1.49M	Sell	697,302 -43,261	-6%	-$107K	﹤0.01%	3074
2022 Q4	$1.99M	Buy	740,563 +53,182	+8%	+$155K	﹤0.01%	2996
2022 Q3	$2.23M	Buy	687,381 +13,259	+2%	+$59.9K	﹤0.01%	2964
2022 Q2	$3.29M	Buy	674,122 +766	+0.1%	+$4.71K	﹤0.01%	2779
2022 Q1	$5.13M	Buy	673,356 +201,487	+43%	+$1.56M	﹤0.01%	2573
2021 Q4	$4.36M	Buy	471,869 +2,621	+0.6%	+$27.8K	﹤0.01%	2772
2021 Q3	$6.68M	Sell	469,248 -13,288	-3%	-$206K	﹤0.01%	2555
2021 Q2	$8.02M	Buy	482,536 +151,586	+46%	+$2.83M	﹤0.01%	2525
2021 Q1	$6.03M	Sell	330,950 -1,646	-0.5%	-$22.3K	﹤0.01%	2636
2020 Q4	$2.5M	Buy	332,596 +63,304	+24%	+$301K	﹤0.01%	3082
2020 Q3	$1.03M	Sell	269,292 -9,852	-4%	-$38.9K	﹤0.01%	3381
2020 Q2	$1.07M	Buy	279,144 +73,533	+36%	+$265K	﹤0.01%	3327
2020 Q1	$664K	Buy	205,611 +52,249	+34%	+$224K	﹤0.01%	3369
2019 Q4	$737K	Buy	153,362 +37,238	+32%	+$236K	﹤0.01%	3481
2019 Q3	$763K	Buy	116,124 +75,058	+183%	+$418K	﹤0.01%	3462
2019 Q2	$312K	Buy	41,066 +23,540	+134%	+$173K	﹤0.01%	3688
2019 Q1	$131K	Buy	+17,526	New	+$350K	﹤0.01%	3867

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Northern Trust's ORGO Position: Q2 2026 in Review

Northern Trust increased its Organogenesis Holdings (ORGO) stake by 5.4% in Q2 2026, buying an estimated $73.7K and bringing the position to 584,577 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Northern Trust first reported a position in ORGO in Q1 2019 and has held it in 30 quarters since. The position peaked at $8.02M in Q2 2021. 135 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

Northern Trust held 584,577 shares of Organogenesis Holdings worth $1.42M as of Q2 2026.
Northern Trust bought 30,149 Organogenesis Holdings shares in Q2 2026, an estimated $73.7K.
Organogenesis Holdings made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3329 holding.
Northern Trust first reported a position in Organogenesis Holdings in Q1 2019 and has held it in 30 quarters since.
Northern Trust's Organogenesis Holdings position peaked at $8.02M in Q2 2021.
135 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.